Self-reported Medicinal Cannabis Use as an Alternative to Prescription and Over-the-counter Medication Use Among US Military Veterans

被引:6
作者
McNabb, Marion [1 ]
Durante, Katherine A. [2 ]
Trocchio, Sarah [1 ,3 ]
Ritter, David J. [1 ]
MacCaffrie, Randal [1 ]
Brum, Ann [4 ]
Mandile, Stephen [4 ]
White, Steven [5 ]
机构
[1] Cannabis Ctr Excellence Inc, 80 Piers Pk Lane,3409, Boston, MA 02128 USA
[2] Univ Utah, Dept Sociol, Salt Lake City, UT USA
[3] Rider Univ, Dept Sociol & Criminol, Lawrenceville, NJ USA
[4] Joint Venture & Co, Mansfield, MA USA
[5] Univ Massachusetts, Charlton Coll Business, N Dartmouth, MA USA
关键词
sex; harm reduction; medicinal cannabis; race; unwanted medications; veterans;
D O I
10.1016/j.clinthera.2023.04.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Mental and other physical health concerns and substance use disorder are common and co-occurring events experienced by US veterans. Treatment with medicinal cannabis is a potential alternative to unwanted medication use for veterans, but more clinical and epidemiologic research is needed to understand the risks and benefits.Methods: Data were collected from a cross-sectional, self-reported, anonymous survey asking US veterans about their health conditions, medical treatments, demographics, and medicinal cannabis use along with its self-reported effectiveness. In addition to descriptive statistics, logistic regression models were run to examine correlates of the use of cannabis as a substitution for prescription or over-the-counter medications.Findings: A total of 510 veterans of US military service participated in the survey, which was adminis-tered between March 3 and December 31, 2019. The participants reported experiencing a variety of mental and other physical health conditions. Primary health conditions reported included chronic pain (196; 38%), PTSD (131; 26%), anxiety (47; 9%), and depression (26; 5%). Most participants (343; 67%) reported using cannabis daily. Many reported using cannabis to reduce the use of over-the-counter medications (151; 30%) including antidepressants (130; 25%), anti-inflammatories (89; 17%), and other prescription medications. Additionally, 463 veterans (91% of respondents) reported that medical cannabis helped them to experience a greater quality of life and 105 (21%) reported using fewer opioids as a result of their medical cannabis use. Veterans who were Black, who were female, who served in active combat, and who were living with chronic pain were more likely to report a desire to reduce the number of prescription medications they were taking (odds ratios = 2.92, 2.29, 1.79, and 2.30, respectively). Women and individuals who used cannabis daily were more likely to report active use of cannabis to reduce prescription medication use (odds ratios = 3.05 and 2.26).Implications: Medicinal cannabis use was reported to improve quality of life and reduce unwanted medication use by many of the study participants. The present findings indicate that medicinal cannabis can potentially play a harm-reduction role, helping veterans to use fewer pharmaceutical medications and other substances. Clinicians should be mindful of the potential associations between race, sex, and combat experience and the intentions for and frequency of medicinal cannabis use. (Clin Ther. 2023;45:562-577.) & COPY; 2023 Elsevier Inc.
引用
收藏
页码:562 / 577
页数:16
相关论文
共 59 条
[1]  
Ahmed Waseem, 2016, Gastroenterol Hepatol (N Y), V12, P668
[2]   Cannabis, the Endocannabinoid System and Immunity-the Journey from the Bedside to the Bench and Back [J].
Almogi-Hazan, Osnat ;
Or, Reuven .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) :1-17
[3]  
[Anonymous], webpage
[4]  
[Anonymous], 2018, FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy
[5]   Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010 [J].
Bachhuber, Marcus A. ;
Saloner, Brendan ;
Cunningham, Chinazo O. ;
Barry, Colleen L. .
JAMA INTERNAL MEDICINE, 2014, 174 (10) :1668-1673
[6]   The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial [J].
Bonn-Miller, Marcel O. ;
Sisley, Sue ;
Riggs, Paula ;
Yazar-Klosinski, Berra ;
Wang, Julie B. ;
Loflin, Mallory J. E. ;
Shechet, Benjamin ;
Hennigan, Colin ;
Matthews, Rebecca ;
Emerson, Amy ;
Doblin, Rick .
PLOS ONE, 2021, 16 (03)
[7]   The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder [J].
Bonn-Miller, Marcel O. ;
Brunstetter, Megan ;
Simonian, Alex ;
Loflin, Mallory J. ;
Vandrey, Ryan ;
Babson, Kimberly A. ;
Wortzel, Hal .
CANNABIS AND CANNABINOID RESEARCH, 2022, 7 (02) :214-223
[8]   Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline [J].
Busse, Jason W. ;
Vankrunkelsven, Patrick ;
Zeng, Linan ;
Heen, Anja Fog ;
Merglen, Arnaud ;
Campbell, Fiona ;
Granan, Lars-Petter ;
Aertgeerts, Bert ;
Buchbinder, Rachelle ;
Coen, Matteo ;
Juurlink, David ;
Samer, Caroline ;
Siemieniuk, Reed A. C. ;
Kumar, Nimisha ;
Cooper, Lynn ;
Brown, John ;
Lytvyn, Lyubov ;
Zeraatkar, Dena ;
Wang, Li ;
Guyatt, Gordon H. ;
Vandvik, Per ;
Agoritsas, Thomas .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 374
[9]   What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review [J].
Campbell, Gabrielle ;
Hall, Wayne ;
Nielsen, Suzanne .
INTERNATIONAL REVIEW OF PSYCHIATRY, 2018, 30 (05) :91-106
[10]   State marijuana laws and opioid overdose mortality [J].
Chihuri, Stanford ;
Li, Guohua .
INJURY EPIDEMIOLOGY, 2019, 6 (01)